Pracinostat
As of the edition of 20 October 2026, Pracinostat is a small molecule: went quiet in 2021; acts on HDAC10.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2021
- Kind
- Small molecule
- Registered trials
- 14, 2 stopped early
- Disease areas
- Blood and lymph; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Pracinostat.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HDAC10 | Polyamine deacetylase HDAC10 | Q969S8 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 7 | 6 | 0 | 1 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| S*Bio | Lead sponsor of trials | 2007 to now |
| Helsinn Healthcare | Lead sponsor of trials | 2013 to now |